Stemline Therapeutics, Inc. (STML)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.21 / 12.35
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Biotech's Big Week Finds a Big Winner in Adaptimmune

Biotech's Big Week Finds a Big Winner in Adaptimmune

The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.

3 Languishing Small-Caps That Should Perk Up in 2020

3 Languishing Small-Caps That Should Perk Up in 2020

Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.

Differing Post-Earnings Tales of 2 Small-Cap Underachievers

Differing Post-Earnings Tales of 2 Small-Cap Underachievers

Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.

2 Small-Cap Stocks That Could Be Righting the Ship

2 Small-Cap Stocks That Could Be Righting the Ship

Stemline Therapeutics and Entercom Communications seem to have stabilized after notable declines late in the summer.

Checking In on 2 Small Biotech Names That Had Big Quarters

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

My Strategy for Stemline Therapeutics

"The true New Yorker secretly believes that people living anywhere else have to be, in some sense, kidding." - John Updike The market is little changed from our noon update. It has been a lackluster day of trading in front of the Fed meeting. Not do...

Trial Patient Dies From a Stemline SL-401 Side Effect

Trial Patient Dies From a Stemline SL-401 Side Effect

A trial patient died from a Stemline Therapeutics' SL-401 cancer drug side effect, the family confirmed.

Small IPOs Bring Risks

Small IPOs Bring Risks

Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.

Medical IPOs: Globus Medical, Stemline

Medical IPOs: Globus Medical, Stemline

IPO Desktop President Francis Gaskins likes Globus Medical, but is content to wait for Stemline.